Related Experiment Videos
Pembrolizumab in recurrent advanced cervical squamous carcinoma
Pablo Martínez1, Josep María Del Campo1
1Oncology Department, Clínica Diagonal, Esplugues de Llobregat, Barcelona, Spain.
Immunotherapy
|April 13, 2017
Summary
Recurrent cervical cancer lacks effective treatments. A heavily pretreated patient with advanced squamous cell carcinoma experienced a significant response to the immune checkpoint inhibitor pembrolizumab, offering new hope.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Recurrent, persistent, or metastatic cervical carcinoma has limited treatment options.
- Chemotherapy is standard but offers scarce and unsatisfactory results.
- Immune checkpoint inhibitors show promise in subsets of cancer patients.
Observation:
- A heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix had exhausted all standard treatment options.
Findings:
- The patient demonstrated a striking and prolonged response to pembrolizumab, an immune checkpoint inhibitor.
- This case highlights the potential efficacy of pembrolizumab in refractory cervical cancer.
Implications:
- Identifying patients who benefit from immune checkpoint inhibitors is crucial.
- Pembrolizumab may represent a viable treatment option for advanced, refractory cervical cancer.
- Further research is warranted to define predictive biomarkers for pembrolizumab response in cervical cancer.